Nanosphere Submits Cardiac Test to FDA | GenomeWeb

NEW YORK (GenomeWeb News) – Nanosphere today said that it has submitted a 510(k) application with the US Food and Drug Administration for its cardiac troponin I test.

The firm said that the test is used to provide early diagnosis of myocardial infarction and risk stratification for acute coronary syndromes. The test runs on the firm's Verigene molecular diagnostics platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.